However, the advent of trastuzumab and more recently several other HER2-targeting novel therapies has led to significant improvements in the prognosis, making the diagnosis a "double-edged sword." The current standard first-line therapy for patients with HER2+ metastatic breast cancer (MBC) is a ...
1 HER2-positive breast cancer is aggressive, however, and the prognosis for patients with advanced disease at diagnosis or for those who are resistant to trastuzumab-based regimens remains poor.1,2 During a recent OncLive Peer Exchange®, experts in breast cancer research expressed optimism that ...
Towards personalized treatment for early stage HER2-positive breast cancer Article 13 December 2019 Main The discovery of the human epidermal growth factor receptor 2 (HER2) (King et al, 1985; Schechter et al, 1985), its association with poor prognosis in breast cancer (Slamon et al, 1987...
High number of iNOSM1-like macrophages, both in the center of the tumour (CT) and invasive margin (IM), was significantly associated with improved survival (p = 0.009) while high expression of IDO1 or CD47 in the malignant cells was associated with worsened prognosis (p = 0.018,...
The prognosis for newly diagnosed first-line disease “is very good in terms of median survivals” which are “now approaching 5 years,” said Sara A. Hurvitz, MD. First- and second-line strategies for treatment of patients with HER2-positive, metastatic breast cancer is straightforward, and ...
HER2 gene amplification occurs in approximately 20% of primary breast cancers and is associated with a poor prognosis. Recently, trastuzumab, a humanized murine monoclonal antibody directed against the extracellular domain of HER2, was introduced for the treatment of patients with HER2-overexpressing adva...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, ner
The human epidermal growth factor receptor 2 (HER2) is overexpressed in HER2-positive breast cancer. This confers characteristics associated with an overall poor prognosis, with early metastases to major visceral sites and a relative resistance to chemotherapy. Trastuzumab is a humanised monoclonal ...
Traditionally, breast cancer has not been considered an immunogenic disease, but an increased presence of tumor-infiltrating lymphocytes has consistently been associated with a favorable breast cancer prognosis33. Elevated tumor-associated lymphocyte levels are observed in triple-negative (TNBC) and HER2-...
Academictrialsare now crucial in breast cancer, added Criscitiello. "The prognosis of patients withbreastcancerhas dramatically improved thanks to several new available treatments; we might see a reduced interest from industry to further invest in this disease, especially in trials designed with de-...